Raw high-throughput sequencing reads, but also 454-generated contigs and annotated genomes corresponding to the de novo assembled samples have been deposited in the European Nucleotide Archive under study accession number PRJEB11729.

Introduction {#sec001}
============

Human herpesvirus type 1 (HHV-1), also known as Herpes simplex virus type 1 (HSV-1), has seroprevalence that ranges from 60 to 90% in the general population \[[@pone.0157600.ref001]\]. Despite the majority of the infections being asymptomatic, 15 to 45% of the adult population suffers from recurrent labial lesions \[[@pone.0157600.ref002]\]. In addition, encephalitis and corneal keratitis occur in one per 500,000 and in 30 per 100,000 people per year, respectively \[[@pone.0157600.ref003], [@pone.0157600.ref004]\]. The virus is also increasingly being associated with genital lesions \[[@pone.0157600.ref005]--[@pone.0157600.ref007]\] but no effective vaccine is available at the moment \[[@pone.0157600.ref008]\].

However, several drugs are licensed for the treatment of recurrent HHV-1 infection in immunocompromised individuals as well as prophylaxis in patients undergoing bone marrow or solid organ transplantation. Antiviral drugs used include the nucleoside analogs acyclovir (ACV)--the drug of choice -, and penciclovir (PCV), as well as foscarnet (FOS), a pyrophosphate analog \[[@pone.0157600.ref009]\]. The mechanism of these drugs is through inhibition of the viral DNA polymerase (Pol) by acting as competitive inhibitors and/or as chain polymerization terminators. The mono-phosphorylated nucleoside analog Cidofovir (CDV) also inhibits Pol, but is not approved for the treatment of HHV-1 infections \[[@pone.0157600.ref010]\]. All of them are prone to the selection of resistance mutations within the viral *pol* gene, but ACV and PCV can mainly become ineffective due to the selection of mutations within the thymidine kinase (*TK*) gene, which is essential for their initial activation \[[@pone.0157600.ref011], [@pone.0157600.ref012]\]. Mutations that are selected in TK are normally insertions or deletions in homopolymeric regions (runs of Gs or Cs) that result in frameshift mutations and premature stop codons \[[@pone.0157600.ref013]\].

The genome of HHV-1 is a long -152kbp-, double-stranded DNA molecule with a high G/C content of 68%. It is unequally divided into one long (L) and one short (S) region. Each region contains a unique sequence, called unique long (UL) and unique short (US), which have only one copy per genome and are both flanked by terminal -T- and internal -I- repeated sequences (TLR/ILR, ISR/TSR). These repeats are characterized by low conservation rates, incorporating numerous microsatellite loci, known as Variable Number Tandem Repeats (VNTRs) and palindrome stem loops (oriL and oriS) omnipresent among the genome. A terminal redundancy of approximately 400 bp, known as *a'* sequence, is located at the ends of this linear genome, but also merges the L and the S segments \[[@pone.0157600.ref014], [@pone.0157600.ref015]\]. The inverted repeats and the *a'* sequence domain play a pivotal role in the recombination events that occur between the L and the S segments \[[@pone.0157600.ref016], [@pone.0157600.ref017]\]. These events are thought to be essential for the viral replication and the *in-vivo* infection \[[@pone.0157600.ref018], [@pone.0157600.ref019]\]. HHV-1 strains vary by geographic region, between individuals but also over sequential isolates from the same individual \[[@pone.0157600.ref020], [@pone.0157600.ref021]\]. The repetitive elements are mainly responsible for this heterogeneity and make the full HHV-1 genome-determination a real challenge, even with the use of high-throughput sequencing technology \[[@pone.0157600.ref022]\]. The need to address these sequencing limitations is obvious due to the fact that the repetitive elements are also located within coding regions and, in some cases, are well conserved among different strains \[[@pone.0157600.ref022]\]

To date, several genome sequences of HHV-1, including strain 17 \[[@pone.0157600.ref014], [@pone.0157600.ref015]\], strain KOS \[[@pone.0157600.ref023], [@pone.0157600.ref024]\] and strain McKrae \[[@pone.0157600.ref025], [@pone.0157600.ref026]\], have been described in detail \[[@pone.0157600.ref027]--[@pone.0157600.ref029]\]. Studies of larger HHV-1 genomes pools (n = 7) \[[@pone.0157600.ref030]\] have implemented a map-to-reference assembly approach. *De novo* assembling approaches generally fail to construct full-length genomes \[[@pone.0157600.ref022]\]. A larger set of genomes (n = 20) has been successfully described recently, where reference sequences were used only for the mapping-orientation of the *de novo* generated contigs \[[@pone.0157600.ref027]\]. To date, only Sanger and short-read NGS technology have been used in these studies, with the former thought to be impractical for a genome on these dimensions and the latter, to have issues regards genome assembly especially with the resolution of repetitive elements \[[@pone.0157600.ref022]\].

Oxford Nanopore Technologies (ONT) recently released "MinION", a USB3.0-interfaced sequencer -initially available only to the participants of ONT's Minion Access Program (MAP)- which is capable of producing hundreds of megabases of data per run, delivering extra-long reads, exceeding 100,000bp in length. These reads, despite their low accuracy which did not exceed 72% for the double-strand sequenced reads (2D) in the first version of the sequencer \[[@pone.0157600.ref031]\], have been used in combination with other sequencing platforms that deliver shorter reads of higher accuracy, to improve the hybrid *de novo* assembly of genomic regions that are difficult to be resolved \[[@pone.0157600.ref032]\].

In the present study we employ culture-isolated HHV-1 clinical samples, that were phenotypically characterized for antiviral drug susceptibility, and longer read-lengths derived from both Roche 454 GS Junior and Minion sequencing platforms to prove that MinION is capable of improving the reference-free *de novo* assembly of the viral genome and to pass through repetitive elements that terminate the contigs generated by the 454 platform alone. We also show that the use of longer reads reveals rearrangement phenomena in *de novo* assembled contigs that suggest the existence of non-canonical HHV-1 genomes in our cultures.

Results {#sec002}
=======

Experimental design {#sec003}
-------------------

We used two different NGS technologies, these being Roche 454 and MinION, to sequence 18 HHV-1 genomes from cell culture-isolated clinical samples derived from 13 patients. Multiple -sequential- samples were obtained from 3 patients. Seven isolates from 4 patients in total were sequenced by both technologies ([Table 1](#pone.0157600.t001){ref-type="table"}). Each technology required different protocols for library preparation and sequencing. We conceived a hybrid pipeline to filter, combine and evaluate the 454 and the MinION data using MIRA assembler \[[@pone.0157600.ref033]\] and LINKS \[[@pone.0157600.ref034]\] as described in the materials and methods section. Using "bedtools"\[[@pone.0157600.ref035]\] we found that the 454 read coverage across the genome varied. There was a drop in the average normalized coverage observed over genomic regions with higher GC content and vice versa ([Fig 1A](#pone.0157600.g001){ref-type="fig"}). This phenomenon was consistent across all samples tested and more pronounced over the terminal and internal repeated sequences (TLR/ILR, ISR/TSR). Most of the discontinuous contigs were also observed over these regions ([Fig 1B](#pone.0157600.g001){ref-type="fig"}). For 454 sequencing, the read lengths ranged up to 1,090bp with a mean of 378.96bp ± 45.81. In contrast, for Minion sequencing, the read lengths ranged up to 210,511bp with a mean of 930.62bp ± 526.30 ([S1 Fig](#pone.0157600.s001){ref-type="supplementary-material"}).

![454 read coverage, GC content and comparative mapping of contigs across the genome map.\
(A): Relative normalized read coverage per sample (454 data) -blue and purple bars represent values beyond and below the average read coverage of the mapping assembly- in correlation with the relative GC content across the reference genome (NC_001806.2) -orange and green bars represent values beyond and below the average GC content- (B): Comparative mapping of solo 454 (brown) and hybrid 454/MinION (yellow) generated contigs. (C): Repetitive elements plotting across the reference genome (NC_001806.2)--"a" sequence in blue, VNTRs in red, stem loops in yellow bars-. (D): Basic structure of the HSV1 genome; UL and US (dark grey) stand for Unique Long and Unique Short region respectively, while TR(L/S) and IR(L/S) (light blue) stand for Terminal and Internal -inverted- Repeats flanging the UL and the US region respectively. Genes (light grey) and coding sequences (light green).](pone.0157600.g001){#pone.0157600.g001}

10.1371/journal.pone.0157600.t001

###### Solo-454 vs. hybrid 454-MinION *de novo* assembly metrics.

![](pone.0157600.t001){#pone.0157600.t001g}

                             Statistics without reference   Genome statistics                                                                    
  ---------------- ---- ---- ------------------------------ -------------------- --------- --------- ------- ------- ------- --------- --------- --------
                                                                                                                                                  
  p1A_454          21   9    62,373                         136,935              45,352    45,352    66.75   89.85   1.099   62,312    45,352    5,665
  p1A_454_minion   18   6    111,746                        136,978              111,746   111,746   66.65   87.78   1.065   107,664   111,746   6,270
                                                                                                                                                  
  p2A_454          26   10   55,661                         148,323              45,492    14,325    67.23   95.05   1.126   53,278    45,492    14,325
  p2A_454_minion   29   10   108,432                        149,533              108,432   13,725    67.28   96.68   1.143   108,421   108,432   13,725
                                                                                                                                                  
  p2B_454          39   11   111,943                        163,752              111,943   12,873    67.74   95.80   1.204   111,943   111,943   12,873
  p2B_454_minion   34   11   111,940                        161,088              111,940   15,115    67.56   95.87   1.179   111,940   111,940   15,115
                                                                                                                                                  
  p2C_454          22   10   54,727                         147,080              30,026    16,316    67.49   92.23   1.087   54,727    30,026    16,316
  p2C_454_minion   20   9    76,134                         148,065              76,134    17,656    67.53   92.00   1.092   76,133    76,134    17,656
                                                                                                                                                  
  p5A_454          66   33   19,559                         163,748              5,915     2,005     66.4    91.77   1.272   19,559    7,362     2,339
  p5A_454_minion   58   31   20,635                         159,894              8,585     2,037     66.59   91.10   1.274   20,635    8,585     2,318
                                                                                                                                                  
  p5B_454          39   21   20,715                         147,686              8,954     5,706     66.59   90.68   1.181   20,715    8,954     5,577
  p5B_454_minion   37   19   26,999                         147,043              13,669    5,707     66.58   90.74   1.171   26,999    13,669    5,577
                                                                                                                                                  
  p17_454          31   9    62,781                         150,948              45,598    13,298    67.7    94.82   1.114   62,778    45,598    13,298
  p17_454_minion   29   7    62,781                         150,940              45,598    16,151    67.7    91.39   1.111   62,778    45,598    16,151

The hybrid *de novo* assembly of HHV-1 genomes using 454 and MinION data {#sec004}
------------------------------------------------------------------------

We found that the *de novo* assembly of the 454-derived HHV-1 genomes was improved by the use of MinION reads through a hybrid assembly protocol. In detail, the number of contigs was reduced while the N(G)50 and the N(G)75 increased across all the 7 samples sequenced by both technologies, with the exception of sample p2A, where the number of the hybrid 454-MinION contigs increased (29 vs. 26 for the 454 contigs). This was probably due to the increased host (VERO cells) contaminating genomic DNA in this particular sample, since only 0.77% of the total MinION reads were mapped on HHV-1 reference ([S1 Fig](#pone.0157600.s001){ref-type="supplementary-material"}). As the extra contigs were smaller than 1,000bp, they only influenced the N75 value of the hybrid assembly (13,725 vs. 14,325 for the 454 contigs), while two larger contigs were merged, leading to an increased N50 value (108,432 vs. 45,492 for the 454 contigs). No other association between the host genomic DNA and the outcome of the assemblies was observed. The generation of the larger contigs was also assisted by the MinION reads in all but 2 cases, where the larger contig was not improved (samples p2B and p17). The genome coverage remained almost unchanged in most of the samples, while it was reduced by 2.1% and 3.4% in the hybrid assemblies of samples p1A and p17 ([Table 1](#pone.0157600.t001){ref-type="table"} and [Fig 2](#pone.0157600.g002){ref-type="fig"}).

![Evaluation of solo 454 and hybrid 454/MinION de-novo assemblies.\
Contigs Generated by 454 reads are in red while hybrid contigs generated by 454 and MinION reads are in blue. Left column: Cumulative assembly length plotted against the number of the contigs of each individual assembly. Right column: NGx value resulted by the alignment of the contigs on the reference HHV-1 genome.](pone.0157600.g002){#pone.0157600.g002}

The effect of hybrid assembly on deciphering structural variability and non-canonical contigs of HHV-1 genomes {#sec005}
--------------------------------------------------------------------------------------------------------------

To investigate if MinION sequencer is capable of enhancing the mining of non-canonical HHV-1 genomes, we used MAUVE \[[@pone.0157600.ref036]\] to compare misaligned contigs (those that are not aligned in a canonical way to the reference during the assembly evaluation with QUAST \[[@pone.0157600.ref037]\]) generated from solo-454 and hybrid 454-MinION assemblies. We identified a total of 8 non-canonical contigs in 5 out of 7 samples that were used in the hybrid assemblies. One of these contigs was identified only in the hybrid assembly of sample p2B and not in the solo-454 assembly. The remaining non-canonical contigs were identified in both the solo-454 and the hybrid assemblies. We confirmed these contigs by using them as reference sequences and mapping the 454 reads against them, to visually inspect the continuity of the mapping assembly over the rearrangement junctions. Detailed analysis revealed possible rearrangement events only within the UL region of samples p1A, p17 and in one contig of p2A while the second identified contig of sample p2A and the contigs found in sample p5A suggested rearrangements between the UL and the T/IRS regions. In the case of sample p2B the identified contigs suggested rearrangements between the UL and the T/IRL regions but also between the T/IRL and the T/IRS regions ([Fig 3](#pone.0157600.g003){ref-type="fig"}).

![Detection of non-canonical contigs.\
Similarity plots between 2 representative non-canonical contigs (middle panel of each screenshot) and the reference genome (strain 17) (top panel of each screenshot). Plots below the base line indicate inverted sequences (plus/minus strand alignment). The coordinates of the edges of each rearranged fragment are below while the coordinates of the disrupted/nearby genes are above the reference plots. Confirmative 454-mapping alignments and coverage of the respective supporting reads are shown below each contig.](pone.0157600.g003){#pone.0157600.g003}

Genetic variability and detection of mutations associated with antiviral resistance across the HHV-1 genome {#sec006}
-----------------------------------------------------------------------------------------------------------

Full genome sequencing of HHV-1 samples will be useful in understanding the full extent of the natural intra- and inter-host sequence variability as well as variability resulting from selective pressure e.g. antiviral therapy. Using *samtools* package \[[@pone.0157600.ref038]\] snpEff (v3.6c) \[[@pone.0157600.ref039]\] and snpSift (v3.6c) \[[@pone.0157600.ref040]\] for variation calling and filtering, and R scripts for basic computations, we estimated the average mutation rate per gene across the HHV-1 genome in these samples taken from patients undergoing antiviral therapy. We omitted the three genes (RL1, RL2, RS1) included in the TLR/ILR and ISR/TSR regions from this analysis due to the lower read coverage over these regions which resulted in fragmented open reading frames. UL15, UL20, UL45, UL55 and UL32 were the 5 most conserved genes as only 0.1%, 0.8%, 1.1%, 1.6% and 2.0% of their amino acids had been mutated at least once within the sample pool, while UL1, UL43, US7, UL23 and UL49A genes accumulated the majority of the non-synonymous mutations across the genome, with 53.3%, 48.7%, 40.1%, 35.2% and 33.6% amino acid changes respectively ([Fig 4](#pone.0157600.g004){ref-type="fig"}).

![Conservation of the sequenced genomes.\
Relative -cumulative- amino acid mutation frequency across the HHV-1 reference genes. RL1, RS1 and RS2 have been omitted due to reduced read coverage over the inverted repeated regions](pone.0157600.g004){#pone.0157600.g004}

Next, we investigated amino acid changes and genetic variability that could be associated with the development of antiviral resistance. We identified several known and novel mutations in the TK and/or DNA polymerase genes of the samples exhibiting reduced phenotypic antiviral drug susceptibility ([Table 2](#pone.0157600.t002){ref-type="table"}). Previously identified mutations that were detected include A719V and S724N in UL30; A93V, H58R, Q250stop and several single nucleotide insertions resulting in a premature stop codon in UL23 \[[@pone.0157600.ref009], [@pone.0157600.ref013], [@pone.0157600.ref041]--[@pone.0157600.ref043]\]. Two novel mutations were identified in UL23, these being V204G and Y172S. The former is located in a non-conserved region of the gene whereas the latter is located within the nucleotide-binding site and C and F substitutions at that position have been previously described to result in ACV resistance \[[@pone.0157600.ref041], [@pone.0157600.ref042]\].

10.1371/journal.pone.0157600.t002

###### Phenotypic drug susceptibility testing in HHV-1 clinical samples.

Natural polymorphisms and drug resistance mutations in TK and Pol genes.

![](pone.0157600.t002){#pone.0157600.t002g}

  Sample   Clinical Info                                                Time   Drug susceptibility profile [^a^](#t002fn001){ref-type="table-fn"}   Thymidine Kinase (TK-UL23) [^b^](#t002fn002){ref-type="table-fn"}   Polymerase (Pol-UL30) [^b^](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                         
  -------- ------------------------------------------------------------ ------ -------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------- ----------- ------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------- --------------------------------------------------- --------- ----------------------
  p1A      bone marrow transplant; ACV therapy                          0      **\>40**                                                             9.67                                                                92.13                                                          2.84        C6G, N23S, K36E, L42P, A265T, W293R, V348I                                      **A93**                                           Novel, (Schubert et al., 2014: unclear)   S33G, **E860K**, V905M, **G985E** P1124H, T1208A    None      
  p1B                                                                   147    1.17                                                                 2.86                                                                86.86                                                          15.46       C6G, N23S, K36E, L42P, A265T, W293R, V348I                                      None                                                                                        S33G, **E860K,** V905M, **G985E**, P1124H, T1208A   None      
  p2A      recurrent HSV keratitis; ACV therapy                         0      *21*.*63*                                                            **\>160**                                                           \<50                                                           6.09        C6G, N23S, K36E, R41H                                                           G ins to 7Gs nt. 430--436, stop codon at AA 224   Andrei et al., 2013                       S33G, **E992K,** A1203T, T1208A                     None      
  p2B                                                                   196    1.3                                                                  4.05                                                                77.47                                                          13.45       C6G, N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E, W293R, N376H   None                                                                                        S33G, **E992K,** A1203T, T1208A                     None      
  p2C                                                                   535    **\>40**                                                             **\>160**                                                           162.67                                                         8.75        C6G, N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E, N376H          **V204G**                                         None                                      S33G, A1203T, T1208A                                None      
  p2D                                                                   780    **\>40**                                                             **148.48**                                                          216.31                                                         3.94        C6G, N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E, W293R, N376H   **V204G**                                         None                                      S33G, **S914L,** A1203T, T1208A,                    None      
  p3       renal transplant, GVHD; ACV therapy                          0      *27*.*37*                                                            **\>160**                                                           100                                                            3.61        E146G                                                                           A ins at nt. 438, stop codon at AA 227            Andrei et al., 2013                       S33G, A562T, D672N, V905M, P1124H, T1208A           None      
  p5A      bone marrow transplant; ACV therapy                          0      **\>40**                                                             **\>160**                                                           85.86                                                          4.13        N23S, K36E, R89Q,                                                               G ins to 7Gs nt. 430--436, stop codon at AA 224   Andrei et al., 2013                       S33G, D672N, V905M, P920S, T1208A                   None       
  p5B                                                                   8      0.66                                                                 4.94                                                                87.83                                                          13.51       N23S, K36E, R89Q, A265T                                                                                                                                                     S33G, D672N, V905M, P920S, T1208A                   None       
  p6       unknown                                                      0      0.57                                                                 2.48                                                                99.28                                                          4.39        A265T, W293R, V348I                                                             None                                                                                        **S911N,** T1121M, P1124H, T1208A                   None      
  p7       haematopoietic stem cell transplant; ACV therapy             0      **\>40**                                                             **154.4**                                                           97.67                                                          3.47        N23S, K36E, R89Q                                                                G ins to 7Gs nt. 430--436, stop codon at AA 224   Andrei et al., 2013                       S33G, T1208A                                        None      
  p9       ACV therapy                                                  0      *35*                                                                 **123.48**                                                          86.67                                                          4.46        C6G, N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E, W293R, N376H   H58R                                              Piret & Boivin, 2011                      S33G, A429T, V905M, P1124H, T1208A                  None      
  p10      unknown                                                      0      *34*.*04*                                                            **\>160**                                                           95.37                                                          3.5         G240E                                                                           Q250stop                                          Sauerbrei et al., 2011                    S33G, A102T, V905M, P920S                           None      
  p11      post allograft, relapsed acute myeloid leukemia              0      *5*.*91*                                                             5.16                                                                130.43                                                         5.68        C6G, N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E, W293R          None                                                                                        S33G, V905M, A1203T, T1208A,                        A719A/V   Piret & Boivin, 2011
  p12      eczema herpeticum; ACV therapy                               0      **\>40**                                                             **\>160**                                                           110.82                                                         2.99        G240E, A265T, R281Q, W293R                                                      **Y172S**                                         None                                      None                                                None      
  p15      Allogenic haematopoietic stem cell transplant; ACV therapy   0      **\>40**                                                             **155.56**                                                          143.24                                                         5.08        C6G, N23S, K36E                                                                 G ins to 7Gs nt. 430--436, stop codon at AA 224   Andrei et al., 2013                       S33G, V905M, A1203T, T1208A                         None      
  p17      ACV therapy                                                  0      *5*.*43*                                                             *14*.*6*                                                            **700.78**                                                     **39.58**   C6G, N23S, K36E, L42P, G251C, A265T, W293R                                      None                                                                                        S33G, **S239L,** V905M, P1124H, A1204T, T1208A      S724N     Piret & Boivin, 2011
  p18      unknown                                                      0      *17*.*08*                                                            *20*.*81*                                                           **681.63**                                                     23.18       G240E, A265T, R281Q                                                             None                                                                                        S1123L, P1124H, T1208A                              S724N     Piret & Boivin, 2011

a: Definitions of phenotypic drug susceptibility classification: Acyclovir (ACV): \<3uM, 3-40uM, \>40uM; Pencyclovir (PCV): \<10uM, 10-40uM, \>40uM; Foscarnet (FOS): \<250uM, 250-400uM, \>400uM; Cidofovir (CDV): \<24uM, 24-30uM, \>30uM for sensitive (normal type), intermediate (*italics*) and resistant (**bold type**) samples, respectively.

b: Novel drug resistance mutations (DRMs) and novel natural polymorphisms are in bold.

Multiple comparisons among the available sequential samples of patients 1, 2 and 5 did not reveal any difference in their genomic variability, but we were able to identify cooption and also loss of drug resistance mutations during the follow-up ([Table 2](#pone.0157600.t002){ref-type="table"}).

Discussion {#sec007}
==========

The *de novo* assembly of HHV-1, and other herpesviruses, is challenging due to the increased length and the unique structure of the genome, which incorporates extended regions that are repeated (internal and terminal inverted repeats) and omnipresent VNTRs that usually exceed the read length of existing next generation sequencing platforms \[[@pone.0157600.ref022], [@pone.0157600.ref044], [@pone.0157600.ref045]\]. In this study we investigated the potential of a newly released sequencer, the MinION, to improve the *de novo* assembly pipeline of HHV-1 by assisting with the length of contigs generated by the Roche 454 GS Junior Sequencer. We also present relevant information about the structural variability of the samples and we describe how the GC content poses one more barrier towards the full genome sequencing of the HHV-1 genome.

To date, only platforms that deliver shorter read lengths have been used to sequence the HHV-1 genome \[[@pone.0157600.ref022], [@pone.0157600.ref046]\]. The MinION sequencer has been used to successfully improve the *de novo* assemblies of data generated by Illumina HiSeq platforms through the increased length of reads that it produces \[[@pone.0157600.ref032]\]. Our results suggest for the first time that MinION sequencer is capable of improving the *de novo* assemblies derived from Roche 454 GS Junior sequencer, which delivers increased read lengths (up to \~600bp) compared to Illumina platforms. 454 GS Junior has higher accuracy (reaching 99%) compared to the MinION sequencer (\~80%) \[[@pone.0157600.ref032], [@pone.0157600.ref047]\], but the error-profile largely depends on the sequence composition of the template---being less effective over homo-polymeric regions \[[@pone.0157600.ref048]\], which are quite common across HHV-1 genome.

We used MIRA, a whole genome sequence assembler, in all our *de novo* assemblies as it provides the option of hybrid assembly and it has been reported to deliver longer contigs (N50\~120,000bp) for Roche 454 GS Junior reads \[[@pone.0157600.ref048]\]. In most of the samples tested in this study there was an overall improvement in the hybrid assemblies with regards to the N(G)50/75 values and the larger contig generated, compared to the corresponding solo-454 assemblies. The minor drop in the genome coverage observed in some cases, maybe due to multiple mappings of -small- 454 contigs that were merged into larger ones in the hybrid assemblies. This is highly likely due to the repetitive nature of the HHV-1 genome that gives the opportunity for smaller contigs to map into multiple positions. For samples p2A and p2C, we managed to merge the two largest contigs of the 454 assemblies, as the MinION reads transverse the oriL palindrome sequence (62,403--62,547bp in strain 17) (Figs [2](#pone.0157600.g002){ref-type="fig"} and [5](#pone.0157600.g005){ref-type="fig"}). This region of the HHV1 genome is difficult to read through, as most of the 454-generated assemblies failed to generate a continuous contig through it. A possible reason for this failure is the lower read coverage that was consistently observed over the palindrome ([Fig 1](#pone.0157600.g001){ref-type="fig"}), which might be caused by the inability to read sequence over the secondary structure that it forms. Secondary structures are a common problem in Pyrosequencing as they give alternative priming sites on the template and thereby generate high background noise \[[@pone.0157600.ref049]\]. This is not the case for the MinION sequencer, which has specially developed chemistry for analysing only single-stranded DNA molecules through its nanopores, thus denaturing secondary structures. The extensive length of the MinION reads allowed the merging of contigs that were disrupted by repetitive elements across the HHV-1 genome ([Fig 1](#pone.0157600.g001){ref-type="fig"} and [S2 Fig](#pone.0157600.s002){ref-type="supplementary-material"}).

![**Mapping of 454-Roche (A) and Nanopore-MinION (B) reads over the oriL palindrome sequence (id38, 62403 -- 62547bp in strain 17).** Long MinION reads (in red, blue, green) assist the bridging of discontinuous 454 contigs. (C): genome annotation.](pone.0157600.g005){#pone.0157600.g005}

Based on the technique of molecular combing, structural variances and non-canonical genomes that incorporate internal duplications, deletions or rearrangements are shown to be present in HHV-1 cultures \[[@pone.0157600.ref050]\]. Here we identify these events, based on non-canonical contigs that are generated from the reference-free, *de novo* assembly of 454 and MinION reads. One of these contigs was identified only in the hybrid 454/MinION assembly of sample p2B ([Fig 3](#pone.0157600.g003){ref-type="fig"}). The reference-free approach allows the mining of minority reads that correspond to the structural variances of the viral genome, which would otherwise have been ignored using the reference sequence. We provide strong evidence of the existence of these structural variances by using the identified non-canonical contigs as reference sequences and by re-mapping the 454 reads against them. This allowed the mapping of 454 reads that had been ignored during the reference mapping assembly of the respective samples. Visual inspection of the original alignments over the coordinates that correspond to the recombination points of the non-canonical contigs, confirmed the continuity of the alignments, suggesting the co-existence of the canonical and non-canonical genomes in the same sample. This observation is also supported by a recent study \[[@pone.0157600.ref027]\].

The GC content across the HHV-1 genome has been correlated with reduced read coverage regions in mapping assemblies \[[@pone.0157600.ref030]\]. Most of the times these regions were the inverted IRS and TRS, which also incorporate numerous VNTRs. Our analysis is consistent with the study of Szpara et al \[[@pone.0157600.ref022]\] which demonstrated that VNTRs were responsible for disrupting the *de novo* assembly of contigs both for strain F and for the clinical isolate H129. The relative normalized read coverage in our mapping assemblies tended to be reduced wherever the relative GC content across the reference genome was increased in all of the 18 454-sequenced samples ([Fig 1](#pone.0157600.g001){ref-type="fig"}, only the seven 454- and MinION-sequenced samples presented). MinION reads did not substantially assist the merging of contigs within the demanding inverted repeats, especially the IRS and the TRS. These regions are characterised by low complexity, which in combination with the low accuracy of MinION reads, may have resulted in conflicting assemblies. It is also possible that these regions might by polymorphic among quasispecies within the same sample, which would then produce conflicting assemblies. This will probably be improved by the new MinION sequencer version, which has decreased sequencing error rates and improved sequencing accuracy.

Although nucleotide differences are dispersed throughout the HHV-1 genome, the genes are not equally conserved. The filtered non-synonymous mutations mined from 18 samples in this study, revealed that some genes differ substantially from the reference (cumulative up to 53.3%) while others were extremely conserved (cumulative down to 0.1%). Ushijima et al \[[@pone.0157600.ref028]\], describing HHV-1 mutant HF10, also showed a relatively high divergence in proteins UL1, UL2, UL11, UL44, US1, US7, US8.5, US10 and US12. Kolb et al \[[@pone.0157600.ref030]\] sequenced 7 samples in a multiplex format and reported UL43, UL1, UL49A, UL11, US4 and US7 as the most variable genes. Our observations were similar, with the exception of US4 gene, which demonstrated only moderate variation in our samples and UL23 gene, which was the 4^th^ most variable in our samples but had moderate variation in the same study (yet still, within the 10 more variable genes). UL23 (TK gene) is where the majority (\>90%) of the drug resistance mutations occur. This might be correlated with the fact that the cohort studied here is of patients undergoing antiviral therapy. The size and the demographic characteristics of the sample pools but also the different informatics pipelines used for the variation calling may explain the differences observed between the two studies. Genes UL16, UL15, UL45, UL28 and UL3, which were reported among the most conserved, also demonstrated low variation levels (up to 5.2%) in our study ([Fig 4](#pone.0157600.g004){ref-type="fig"}).

Our results indicate that future relevant studies focusing on the resolution of the VNTRs and the repetitive regions of the genome should make use of longer reads derived from 3^rd^ generation sequencers like MinION. Hopefully, increased accuracy of the long-read technology, in combination with the depth of short-read platforms, will improve the full genome *de novo* assembly of HHV-1, which remains a challenging task.

Materials and Methods {#sec008}
=====================

Cell culture isolation and phenotypic drug susceptibility testing of HHV-1 clinical samples {#sec009}
-------------------------------------------------------------------------------------------

In this study, we used a total of 18 HHV-1 isolates from 13 different patients ([Table 2](#pone.0157600.t002){ref-type="table"}). The viruses were isolated from clinical swabs taken from patient lesions by the attending clinician and sent to the National Reference Laboratory at Public Health England for routine diagnosis and characterization of drug resistance. The viruses were isolated and titrated using monolayers of African green monkey kidney cells (Vero cells). Phenotypic antiviral susceptibility testing for HHV-1 was performed as previously described \[[@pone.0157600.ref051]\]. Briefly, viral isolates were used to infect a sub-confluent monolayer of Vero cells at a concentration of 75 plaque forming units (PFU) per well. After 1 hour incubation at 37°C cells were overlaid with CMC medium (4% Carboxymethyl cellulose in PBS) containing a serial dilution of the antiviral drugs acyclovir (ACV), pencyclovir (PCV), cidofovir (CDV) and foscarnet (FOS) or CMC alone, as a no drug control, and incubated for a further 72 hours until plaques became apparent. Cells were fixed with 10% formalin and stained with crystal violet before enumeration of the plaques. The data was then used to determine IC~50~ values for all four drugs using linear regression. Definitions of phenotypic drug susceptibility classification as sensitive or resistant were as follows: ACV, \<3μM or \>40μM; PCV, \<10μM or \>40μM; CDV, \<24μM or \>30μM; FOS, \<250μM or \>400μM, respectively. Any IC~50~ values falling in between these sensitive and resistant cut-offs were reported as intermediate resistance.

The samples were anonymized by removal of any patient identifiable information and assignment of a non-specific project number before being subjected to genetic characterization as described below.

Preparation of viral DNA for sequencing {#sec010}
---------------------------------------

To prepare viral DNA for sequencing we infected confluent monolayers of Vero cells at 5 PFUs/cell for 24 to 48 hours, until cytopathic effect became apparent.

Viral supernatants were harvested by freeze-thawing and passed through a 0.45 μM filter. Four ml of the virus supernatant was incubated with 20 U/ml DNase (Promega) for 3 hours at 37°C before loading onto a 1.5 ml 20% sucrose cushion and centrifuged at 100,000g for 1 hour. Viral pellets were re-suspended in TE containing DNase chelator and extracted with the PureLink® Viral RNA/DNA Mini Kit (Invitrogen) following manufacturer's instructions.

454 and MinION sequencing {#sec011}
-------------------------

Approximately 500 ng of extracted viral nucleic acid from each sample was processed for sequencing by the Roche 454 GS Junior NGS platform following the manufacturer's protocol for sequencing viral genomic DNA (gDNA). Briefly, the viral gDNA was subjected to fragmentation by nebulization to generate fragments between 500 to 800 base pairs long. The fragmented viral DNA was then used to create a library using the Rapid Library Preparation Kit (Lib-L), which ligates short DNA adaptors. The short DNA adaptors contain unique multiplex identifiers (MIDs), which allow sequencing of multiple samples in a single run. The DNA was amplified by emulsion PCR before sequencing and all 18 samples were multiplexed in a single run on a Roche 454 GS Junior System.

MinION sequencing libraries were prepared according to MAP003-MinION gDNA Sequencing Kit protocol. Briefly, 1 ug of extracted DNA from 7 -previously 454 sequenced- samples was sheared to approximately 10,000bp with g-Tubes (520079, Covaris, Woburn, Massachusetts, USA). After adding the internal control DNA (phage Lambda DNA), we end-repaired the sheared DNA with NEBNext End-Repair module (New England BioLabs), purified it with Agencourt AMPure XP PCR Purification beads (Beckman Coulter) and dA-tailed it with NEBNext dA-tailing module (New England BioLabs). Finally, we ligated the 3'end T-overhanging hairpin- and Y- formed MinION sequencing adapters to the d-A tailed DNA using NEBNext Blunt/TA Ligase (New England BioLabs). We conditioned and loaded the libraries to the sequencer for a 48hours run, renewing them every 12 hours.

Bioinformatics {#sec012}
--------------

Computational analyses were conducted using open source software packages. The.*ssf* files derived from Roche 454 GS Junior platform, were converted to.*fastq* files using *sff2fastq* utility v0.9.2 (<https://github.com/indraniel/sff2fastq>). The.*fastq* files were quality-controlled with *fastQC* v.0.10.1 (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc>) and the reads were appropriately trimmed using *fastx_trimmer* from *fastx toolkit* v0.0.13 (<http://hannonlab.cshl.edu/fastx_toolkit/index.html>), as there was an occasional drop in their quality after approximately the 450^th^ nucleotide. The reads were mapped against the HSV strain 17 reference genome \[[@pone.0157600.ref014], [@pone.0157600.ref015]\] using *bwa* v0.7.12 \[[@pone.0157600.ref052]\] (default settings) and the resulting alignments were visualized with the *Integrated Genomics Viewer* (IGV) v2.3.60 \[[@pone.0157600.ref053]\].

MinION basecalling was performed via the Metrichor agent (provided by ONT). We converted the.*fast5* reads to.*fasta* files using the poRe v0.5 package for R programming language \[[@pone.0157600.ref054]\]. We used "Biostrings" Bioconductor package v2.38 to assess the read-length characteristics of the MinION sequencer for each individual experiment. The alignment of the reads was performed with *LAST v581* \[[@pone.0157600.ref055]\] setting -T = 1, thus allowing only complete reads to be mapped. We converted the resulting.*maf* alignments to.*sam* using "maf-convert" Python script (<https://github.com/arq5x/nanopore-scripts/blob/master/maf-convert.py>).

We performed the *de novo* assembly of HHV-1 genomes with *MIRA* \[[@pone.0157600.ref033]\] using either the filtered 454 reads alone, or in combination with the MinION reads and configuring the assembler as: job = genome,denovo,accurate \\ -GE:not = 12 -SK:mmhr = 1 -NW:cdrn = no -AS:nop = 3 urd = yes. The hybrid assemblies were further improved using *LINKS* v1.3 \[[@pone.0157600.ref034]\] (default settings). The continuity of the hybrid contigs over discontinuous 454 contigs was verified by visual inspection of the mapping assemblies of both 454 and MinION reads, setting as a threshold the existence of at least 2 MinION reads spanning the discontinuous 454 contigs for at least 500bp on each side ([Fig 5](#pone.0157600.g005){ref-type="fig"}). Unaligned contigs were removed from the output pool and all assemblies were evaluated with QUAST v2.3 \[[@pone.0157600.ref037]\]. To identify rearrangement events we filtered the QUAST-misaligned contigs with BLAST to exclude those suggesting rearrangements at the beginning or at the end of repetitive regions and the remaining were evaluated by visual inspection with MAUVE v2.3.1 \[[@pone.0157600.ref036]\].

We used *abacas* v1.3.1 \[[@pone.0157600.ref056]\] to align the 454 *de novo* generated contigs with the reference genome, using 100Ns to indicate the assembly gaps. We annotated the assemblies using *prokka* v1.11 \[[@pone.0157600.ref057]\] and we converted the.gbk outputs to.embl formatted flat files using *Artemis* v16.0.0 \[[@pone.0157600.ref058]\].

We performed the SNP/INDEL and the consensus calling with the *samtools* package v1.2 \[[@pone.0157600.ref038]\] filtering-in variations with at least 80% read support per position. Using snpEff v3.6c \[[@pone.0157600.ref039]\] the.vcf files where annotated to the reference genome and non-synonymous SNPS/INDELS were further filtered with snpSift v3.6c \[[@pone.0157600.ref040]\] to meet the quality and coverage thresholds of \>20 and \>5, respectively. Using R for basic calculations, we estimated the per-gene mutation frequency by counting the total number of the per-gene variations observed, divided by the length of each protein, using as reference the HSV1 strain 17.

To calculate the mean coverage of 454 reads across the genome, we used *bedtools coverage* v2.24.0 \[[@pone.0157600.ref035]\]. We calculated the normalised coverage after dividing the per position coverage by the total mapped reads of each.*bam* file. We visualised the coverage plots in comparison to GC content across the genome using DNAplotter v10.2 \[[@pone.0157600.ref059]\].

Supporting Information {#sec013}
======================

###### Nanopore-MinION read-length histograms (log10 transformed) and proportion of total reads mapped to the HHV-1 genome (dark grey).

The read-lengths\' distribution but also the total mapped reads varied amongst the MinION runs.

(PDF)

###### 

Click here for additional data file.

###### Comparative analysis of solo (S) 454-Roche and hybrid (H) 454-MinION assemblies across all the repeat regions of HHV-1 genome (strain17).

Regions covered by at least one contig (+) where more in the hybrid assemblies compared to the solo ones, in 3 out of 5 samples tested.

(PDF)

###### 

Click here for additional data file.
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